Acquired resistance to BRAF/MEK inhibitors seems to cause increased production of reactive oxygen species (ROS) in BRAF V600E mutant melanoma cells; this production could be exacerbated and exploited by therapeutic inhibition of HDAC and subsequent downregulation of the SLC7A11 transporter [119]. The gene discussed is HDAC9; the disease is melanoma.